Join us at @ASNKidney #KidneyWk to learn about our ongoing research in kidney disease and our late-stage clinical trials. Find us at booth #510!

#News: We’re presenting new data on an investigational treatment for immunoglobulin A nephropathy (IgAN) at @ASNKidney #KidneyWk 2025. Learn more: https://t.co/oTlD6Xqldx

STARTING SOON: Join our Q3 2025 financial results live webcast at 8:30 AM ET to hear from our CEO and executive team on this quarter’s strong performance. Join here: https://t.co/fvXwZQyzb0 #Earnings $BIIB

Today, we reported our Q3 2025 financial results which reflect strong execution against our strategy. Read more: https://t.co/hspR0WIaiz Forward-looking statements: https://t.co/IZffiUJaju #Earnings $BIIB

We’re in Chicago for #ACR25 where we’ll share how we’re working to advance options for those living with lupus. Find us at booth #451 and visit our website to learn more about our work: https://t.co/CSX6zwGQv6

#News: With @VanquaBio, we announced a license agreement that expands our early-stage immunology pipeline. Learn more: https://t.co/PDsil3lO8J

#News: We’re presenting data from late-stage lupus research at #ACR25 this week. Read more about our work to help improve outcomes for those living with this chronic disease: https://t.co/ARDjT8RJxC

#News: With Eisai, our treatment that offers at-home injections to help patients continue care has been named by @TIME as one of the “Best Inventions of 2025” in the Medical and Healthcare category. Read more: https://t.co/KU4WposAli

#News: With @StokeTx, we presented data on an investigational treatment for Dravet syndrome at the 54th Child Neurology Society (CNS) Annual Meeting. Learn more: https://t.co/s1Oiey2C5G

#News: We announced plans to acquire @AlcyoneTx. With this acquisition, we’ll drive the development & commercialization of an investigational implantable intrathecal device for the delivery of antisense oligonucleotides (ASOs). https://t.co/mdivyVw0qK

#News: The European Commission approved the first treatment for postpartum depression (PPD) in Europe. This approval is a significant step forward for maternal health and women across Europe. Read more about this news: https://t.co/bngTBWTsUj

IgA Nephropathy (IgAN) is the most prevalent form of kidney disease. This week, we’re attending @iigann2025 to share the progress we’re making in advancing options for people living with IgAN. Learn more: https://t.co/rMJDUV9mP9

#News: We’re hosting a virtual investor seminar focused on the potential of our late-stage lupus portfolio. Join us at 10 a.m. ET to learn more: https://t.co/huZhfLxhuv

#News: Together with Eisai, we announced the initiation of a rolling submission to the FDA seeking to expand how treatment may be administered as a starting dose for people living with early Alzheimer’s disease. Read more here: https://t.co/DuNtwHtKpb

#News: Today, with @StokeTx, we announced new data from studies of our investigational medicine for Dravet syndrome at #IEC2025. Read more here: https://t.co/BfphnskK5e

#News: Today, together with Eisai, we announced that the FDA has approved a new dosing option for people living with early Alzheimer’s disease. Learn more: https://t.co/UgvlyyxuY7

#News: Today, with @StokeTx, we announced the planned presentations of new data from studies of our investigational medicine for Dravet syndrome at #IEC2025. Read more: https://t.co/vG1LajV9vu

#News: Together with @StokeTx, we announced the first patient has been dosed in a Phase 3 study for our investigational therapy for Dravet syndrome. Read more: https://t.co/vtyJDrUg1l

We’re heading to the World Transplant Congress 2025 to share how we're helping to advance research for people living with a kidney transplant. Find us at booth #912 and visit our website to learn more about our work: https://t.co/PbqEZlpWTX

STARTING SOON: Join our Q2 2025 financial results live webcast at 8:30 AM ET. Join here: https://t.co/TU34hsyW91 #Earnings $BIIB